YM BioSciences Inc.

YM BioSciences enters agreement to acquire Eximias Pharmaceutical Corporation

Published in Medicine and Law Weekly, May 19th, 2006

YM BioSciences Inc. (YMBA), the cancer product development company, announced it has entered into a definitive agreement to acquire Eximias Pharmaceutical Corporation, Berwyn, Pennsylvania, a privately held pharmaceutical company engaged in the acquisition, development and commercialization of products for the treatment of cancer and cancer-related disorders.

Upon completion of the transaction, Eximias will become a wholly owned subsidiary of YM operating as YM BioSciences USA Inc. and will serve as YM's base of operations in the United States. Eximias employs a seasoned management team and has cash resources in excess of $30 million.

The merger...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Medicine and Law Weekly

Source: Medicine and Law Weekly (2006-05-19)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry